Literature DB >> 25665509

Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results.

Hamidreza Abdi1, Homayoun Zargar1, S Larry Goldenberg1, Triona Walshe2, Farshad Pourmalek1, Christopher Eddy2, Silvia D Chang2, Martin E Gleave1, Alison C Harris2, Alan I So2, Lindsay Machan2, Peter C Black3.   

Abstract

PURPOSE: We aimed to determine the performance of multiparametric magnetic resonance imaging (mpMRI) in the detection of prostate cancer (PCa) in patients with prior negative transrectal ultrasound-guided prostate biopsy (TRUS-B) results.
MATERIALS AND METHODS: Between 2010 and 2013, 2,416 men underwent TRUS-B or an mpMRI or both at Vancouver General Hospital. Among these, 283 men had persistent suspicion of PCa despite prior negative TRUS-B finding. An MRI was obtained in 112, and a lesion (prostate imaging reporting and data system score ≥ 3) was identified in 88 cases (78%). A subsequent combined MRI-targeted and standard template biopsy was performed in 86 cases. A matching cohort of 86 patients was selected using a one-nearest neighbor method without replacement. The end points were the rate of diagnosis of PCa and significant PCa (sPCa) (Gleason > 6, or > 2 cores, or > 50% of any core).
RESULTS: MRI-targeted TRUS-B detected PCa and sPCa in 36 (41.9%) and 30 (34.9%) men when compared with 19 (22.1%) and 14 (16.3%), respectively, men without mpMRI (P = 0.005 for both). In 9 cases (10.4%), MRI-targeted TRUS-B detected sPCa that was missed on standard cores. sPCa was present in 6 cases (6.9%) on standard cores but not the targeted cores. Multivariate analysis revealed that prostate imaging reporting and data system score and prostate-specific antigen density > 0.15 ng/ml(2) were statistically significant predictors of significant cancer detection (odds ratio = 14.93, P < 0.001 and odds ratio = 6.19, P = 0.02, respectively).
CONCLUSION: In patients with prior negative TRUS-B finding, MRI-targeted TRUS-B improves the detection rate of all PCa and sPCa.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Image-guided biopsy; Magnetic resonance imaging; Prostate; Prostatic neoplasms; Targeted biopsy; Ultrasonography

Mesh:

Year:  2015        PMID: 25665509     DOI: 10.1016/j.urolonc.2015.01.004

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  9 in total

1.  Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Authors:  Samrad Ghavimi; Hamidreza Abdi; Jennifer Waterhouse; Richard Savdie; Silvia Chang; Alison Harris; Lindsay Machan; Martin Gleave; Alan I So; Larry Goldenberg; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

Review 2.  Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.

Authors:  Andrew B Rosenkrantz; Sadhna Verma; Peter Choyke; Steven C Eberhardt; Scott E Eggener; Krishnanath Gaitonde; Masoom A Haider; Daniel J Margolis; Leonard S Marks; Peter Pinto; Geoffrey A Sonn; Samir S Taneja
Journal:  J Urol       Date:  2016-06-16       Impact factor: 7.450

3.  Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.

Authors:  Christopher P Filson; Shyam Natarajan; Daniel J A Margolis; Jiaoti Huang; Patricia Lieu; Frederick J Dorey; Robert E Reiter; Leonard S Marks
Journal:  Cancer       Date:  2016-01-07       Impact factor: 6.860

Review 4.  Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.

Authors:  Sangjun Yoo; Jeong Kon Kim; In Gab Jeong
Journal:  Korean J Urol       Date:  2015-06-30

Review 5.  A Review of Imaging Methods for Prostate Cancer Detection.

Authors:  Saradwata Sarkar; Sudipta Das
Journal:  Biomed Eng Comput Biol       Date:  2016-03-02

6.  Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.

Authors:  Ivo G Schoots; Daniel F Osses; Frank-Jan H Drost; Jan F M Verbeek; Sebastiaan Remmers; Geert J L H van Leenders; Chris H Bangma; Monique J Roobol
Journal:  Transl Androl Urol       Date:  2018-02

Review 7.  Magnetic resonance imaging detection of prostate cancer in men with previous negative prostate biopsy.

Authors:  Matthew Truong; Thomas P Frye
Journal:  Transl Androl Urol       Date:  2017-06

Review 8.  Prostate imaging features that indicate benign or malignant pathology on biopsy.

Authors:  Catherine Elizabeth Lovegrove; Mudit Matanhelia; Jagpal Randeva; David Eldred-Evans; Henry Tam; Saiful Miah; Mathias Winkler; Hashim U Ahmed; Taimur T Shah
Journal:  Transl Androl Urol       Date:  2018-09

9.  A Single-center Experience: Does MRI-guided Target Prostate Biopsy Meet Expectations?

Authors:  Türev Demirtaş; Gökhan Sönmez; Şevket T Tombul; Abdullah Demirtaş
Journal:  Cureus       Date:  2019-11-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.